Neurocrine Bioscienc (NBIX) Stock Price, Quote & News

Latest News on NBIX

May 8, 2025, 8:30 AM EDT - 6 days ago

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

May 6, 2025, 4:01 PM EDT - 7 days ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

May 6, 2025, 1:24 PM EDT - 7 days ago

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

May 6, 2025, 8:30 AM EDT - 8 days ago

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

May 5, 2025, 8:33 PM EDT - 8 days ago

Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:01 PM EDT - 8 days ago

Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

May 5, 2025, 8:30 AM EDT - 9 days ago

Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia

Apr 30, 2025, 7:35 PM EDT - 13 days ago

Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Apr 30, 2025, 8:00 AM EDT - 14 days ago

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Apr 24, 2025, 4:05 PM EDT - 19 days ago

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Apr 22, 2025, 6:05 PM EDT - 21 days ago

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Apr 16, 2025, 5:51 PM EDT - 27 days ago

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Apr 4, 2025, 8:00 AM EDT - 5 weeks ago

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

Mar 31, 2025, 8:30 AM EDT - 6 weeks ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

Mar 20, 2025, 8:30 AM EDT - 7 weeks ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Mar 17, 2025, 8:30 AM EDT - 2 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Mar 11, 2025, 4:01 PM EDT - 2 months ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

Mar 5, 2025, 8:30 AM EST - 2 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Feb 27, 2025, 4:05 PM EST - 2 months ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Feb 25, 2025, 4:01 PM EST - 2 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Feb 21, 2025, 8:00 AM EST - 2 months ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Feb 7, 2025, 1:05 PM EST - 3 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Feb 6, 2025, 10:52 PM EST - 3 months ago

Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 4:01 PM EST - 3 months ago

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Feb 4, 2025, 7:52 AM EST - 3 months ago

Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval

Jan 30, 2025, 4:01 PM EST - 3 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Jan 28, 2025, 8:30 AM EST - 3 months ago

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Jan 27, 2025, 4:05 PM EST - 3 months ago

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Jan 23, 2025, 4:05 PM EST - 3 months ago

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Jan 21, 2025, 4:05 PM EST - 4 months ago

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Jan 13, 2025, 7:04 PM EST - 4 months ago

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Jan 8, 2025, 8:30 AM EST - 4 months ago

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Jan 6, 2025, 4:01 PM EST - 4 months ago

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 8:00 AM EST - 5 months ago

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 18, 2024, 10:11 AM EST - 5 months ago

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Dec 13, 2024, 6:55 PM EST - 5 months ago

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 13, 2024, 5:50 PM EST - 5 months ago

US FDA approves Neurocrine Biosciences' genetic disorder drug

Nov 26, 2024, 4:01 PM EST - 6 months ago

Neurocrine Biosciences to Participate at Investor Conferences in December

Nov 8, 2024, 11:02 AM EST - 6 months ago

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Nov 7, 2024, 8:30 AM EST - 6 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Nov 5, 2024, 4:01 PM EST - 6 months ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Nov 4, 2024, 8:30 AM EST - 6 months ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Nov 4, 2024, 8:25 AM EST - 6 months ago

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Oct 30, 2024, 3:11 PM EDT - 6 months ago

Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 7 months ago

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Oct 10, 2024, 7:42 AM EDT - 7 months ago

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 9, 2024, 4:01 PM EDT - 7 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Sep 30, 2024, 8:30 AM EDT - 8 months ago

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Sep 19, 2024, 4:01 PM EDT - 8 months ago

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

Sep 12, 2024, 4:31 PM EDT - 8 months ago

Market Cap	11.45B
Revenue (ttm)	2.36B
Net Income (ttm)	341.30M
EPS (ttm)	N/A
PE Ratio	33.34
Forward PE	28.66
Profit Margin	14.49%
Debt to Equity Ratio	0.00

Volume	1,197,100
Avg Vol	1,625,894
Day's Range	N/A - N/A
Shares Out	98.97M
Stochastic %K	42%
Beta	0.26
Analysts	Strong Sell
Price Target	$161.12